Effects of Oxytocin on Emotion Recognition in Schizophrenia: A Randomized Double-Blind Pilot Study.

Andari E, Massa NM, Fargotstein MD, Taylor NB, Halverson DM, Owens AV, Currin DL, Bhattacharya A, Gitman D, Cuthbert BC, Young LJ, Duncan EJ

Journal of clinical psychopharmacology1 Mar 2021Cited by 12 (Europe PMC)

PMID33587397PMCIDPMC8186294DOI10.1097/jcp.0000000000001367PepBankPUB-33587397

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with schizophrenia, intranasal oxytocin enhanced emotion recognition during an emotion-based ball-tossing game versus placebo, specifically in the game with social cue processing.
In plain wordsIn men with schizophrenia, nasal oxytocin improved emotion recognition in a social ball game compared with placebo.
Peptide
Oxytocin
Outcome
IncreaseEmotion recognition in an interactive ball-tossing game
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Mental health and mood
Studied dose
24 IU · intranasalAs given in this study (human).
Source sentences
Summary
Intranasal oxytocin enhanced the recognition of emotions during an emotion-based ball-tossing game. This improvement was specific to the game that included social cue processing.
1 context sentence(design, population, supporting numbers)
Summary · context
In a male-only parallel randomized placebo-controlled double-blind trial, we investigated the effects of IN-OXT (24 IU) on visual fixation on pictures of faces and emotion recognition in an interactive ball-tossing game that probed processing of social and nonsocial stimuli.
Report a problemFND-3358739701
02HumanRandomized controlled trialEfficacy outcome
In men with schizophrenia, intranasal oxytocin did not affect eye gaze duration on faces versus placebo.
In plain wordsIn men with schizophrenia, nasal oxytocin did not change how long they looked at faces compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeEye gaze duration on faces
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Mental health and mood
Studied dose
24 IU · intranasalAs given in this study (human).
Source sentences
Summary
Intranasal oxytocin did not affect eye gaze duration
1 context sentence(design, population, supporting numbers)
Summary · context
In a male-only parallel randomized placebo-controlled double-blind trial, we investigated the effects of IN-OXT (24 IU) on visual fixation on pictures of faces and emotion recognition in an interactive ball-tossing game that probed processing of social and nonsocial stimuli.
Report a problemFND-3358739702
03HumanRandomized controlled trialEfficacy outcome
In men with schizophrenia, intranasal oxytocin did not affect gaze dwell time on faces versus placebo.
In plain wordsIn men with schizophrenia, nasal oxytocin did not change gaze dwell time on faces compared with placebo.
Peptide
Oxytocin
Outcome
No significant changeGaze dwell time on faces
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Mental health and mood
Studied dose
24 IU · intranasalAs given in this study (human).
Source sentences
Summary
Intranasal oxytocin did not affect eye gaze duration or gaze dwell time on faces in these patients.
1 context sentence(design, population, supporting numbers)
Summary · context
In a male-only parallel randomized placebo-controlled double-blind trial, we investigated the effects of IN-OXT (24 IU) on visual fixation on pictures of faces and emotion recognition in an interactive ball-tossing game that probed processing of social and nonsocial stimuli.
Report a problemFND-3358739703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01568528

Oxytocin as Adjunctive Treatment of Schizophrenia

Emory Universityn = 39Mar 2013 to 15 Mar 2017

Schizophrenia

Trial page ClinicalTrials.govUpdated 4 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.